Comparative Pharmacology
Head-to-head clinical analysis: KETOCONAZOLE versus MYCELEX 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOCONAZOLE versus MYCELEX 7.
KETOCONAZOLE vs MYCELEX-7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits fungal cytochrome P450 14α-demethylase, impairing ergosterol synthesis and disrupting fungal cell membrane integrity.
Clotrimazole, an azole antifungal, inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and increasing membrane permeability.
200-400 mg orally once daily for superficial fungal infections; 400 mg orally once daily for systemic mycoses. Duration varies by indication.
Clotrimazole 100 mg vaginal tablet inserted intravaginally once daily at bedtime for 7 days.
None Documented
None Documented
Biphasic elimination: initial half-life 2-4 hours, terminal half-life 6-10 hours in adults. In severe hepatic impairment, half-life may be prolonged up to 12-20 hours.
Clinical Note
moderateKetoconazole + Tranilast
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Tranilast."
Clinical Note
moderateKetoconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Tolfenamic acid."
Clinical Note
moderateKetoconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Nimesulide."
Clinical Note
moderateThe systemic half-life of clotrimazole following vaginal administration is approximately 0.5–1 hour due to rapid metabolism and elimination. This short half-life reflects minimal systemic absorption (3–10%).
Primarily metabolized in the liver; about 70% of the dose is excreted in feces via bile as metabolites, approximately 20-30% in urine (mostly as inactive metabolites), and less than 5% unchanged.
Primarily via feces as unchanged drug (approx. 50%) and metabolites. Renal excretion of unchanged drug is minimal (<1%) as the drug is poorly absorbed from the vagina. Biliary excretion contributes to fecal elimination.
Category C
Category C
Azole Antifungal
Azole Antifungal
Ketoconazole + Risedronic acid
"The risk or severity of adverse effects can be increased when Ketoconazole is combined with Risedronic acid."